We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

GlaxoSmithKline Consumer Healthcare (Ireland) Ltd

12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
E-mail: customer.relations@gsk.com
Medical Information Direct Line: 1800 441 442

Summary of Product Characteristics last updated on medicines.ie: 10/26/2017
SPC Day Nurse Capsules

Go to top of the page

Day Nurse Capsules

Paracetamol 500mg

Pseudoephedrine Hydrochloride 30mg

Pholcodine 5mg

Go to top of the page

Active ingredients




Quantity mg/cap




Also contains Allura Red (E129).

For a full list of excipients see section 6.1

Go to top of the page

Capsule, hard (Capsule)

The capsule has an orange cap and yellow body, printed with an identifier in black ink. It contains a white powder.

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

For the relief of the major symptoms of colds and influenza.

Go to top of the page
4.2 Posology and method of administration

For oral administration only. To be taken during the day.

Adults and children over 12 years: Two capsules every four hours, up to a maximum of 4 doses (8 capsules) in 24 hours if needed.

Children under 12 years: Not to be given to children under 12 years of age. Elderly: There is no specific requirement for dosage reduction in the elderly. Maximum duration of continued use without medical advice: 7 days. Minimum dosing interval: 4 hours.

Do not exceed the stated dose.

The lowest dose necessary to achieve efficacy should be used.

Should not be used with other paracetamol containing products, decongestants or cough and cold medicines. If symptoms persist consult a doctor.

Hepatic Impairment: Patients who have been diagnosed with hepatic impairment must seek medical advice before taking this medication.

Renal Impairment: Pseudoephedrine is primarily excreted renally. This product should not be used by those with severe renal impairment and should be used with caution in those with mild to moderate renal impairment.

Go to top of the page
4.3 Contraindications

This product is contraindicated in people:

• With a hypersensitivity to paracetamol, pseudoephedrine, pholcodine or any of the excipients. With severe hypertension or severe coronary artery disease.

• With, or at risk of developing, respiratory failure (e.g. those with chronic obstructive airways disease or pneumonia)

• or those with bronchiolitis or bronchiectasis, due to sputum retention.

• Who are receiving other sympathomimetics (such as decongestants, appetite suppressants and amphetamine-like psychostimulants).

• Who are receiving Monoamine Oxidase Inhibitors (MAOIs), or for two weeks after stopping a MAOI drug.

• With severe renal impairment.

• Children under 12 years of age.

Go to top of the page
4.4 Special warnings and precautions for use

Contains paracetamol. Do not use with any other paracetamol-containing products, antihistamines or cold and flu medicines. The concomitant use with other products containing paracetamol may lead to an overdose. Paracetamol overdose may cause liver failure which can lead to liver transplant or death.

Cases of hepatic dysfunction/failure has been reported in patients with depleted glutathione levels, such as those who are severely malnourished, anorexic, have a low body mass index or are chronic heavy users of alcohol.

Caution in patients with glutathione depleted states such as sepsis; the use of paracetamol may increase the risk of metabolic acidosis.


Immediate medical advice should be sought in the event of an overdose, even if you feel well.

Leaflet or combined label/leaflet:

Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of irreversible, serious liver damage.

Caution should be exercised in patients with mild to moderate kidney impairment and in those with hepatic impairment. Underlying liver disease increases the risk of paracetamol- related liver damage.

Caution should be exercised in patients with cardiovascular disease, arrhythmias, hypertension, hyperthyroidism, prostatic enlargement, diabetes, glaucoma, phaeochromocytoma, or in those with chronic or persistent cough, asthma, or where cough is accompanied by excessive secretions.

There have been rare cases of posterior reversible encephalopathy (PRES)/reversible cerebral vasoconstriction syndrome (RCVS) reported with sympathomimetic drugs, including pseudoephedrine. Symptoms reported included sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improved or resolved within a few days following appropriate treatment. Pseudoephedrine should be discontinued and medical advice sought immediately, if signs/symptoms of PRES/RCVS develop.

There have been reports of ischaemic colitis with pseudoephedrine. Pseudoephedrine should be discontinued immediately and medical advice sought if sudden abdominal pain, rectal bleeding or other symptoms of ischaemic colitis develop.

Pholcodine may enhance the CNS effects of alcohol or other CNS depressants. Use with caution in patients taking beta-blockers or other anti-hypertensives.

If symptoms persist medical advice must be sought.

Do not exceed the stated dose.

Do not take with decongestants or cough medicines.

Keep out of the sight and reach of children.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine.

The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol-containing products with increased risk of bleeding; occasional doses have no significant effect.

Concomitant administration of pseudoephedrine hydrochloride-containing products and MAOIs (or within two weeks of stopping of MAOI) may lead to hypertensive crisis.

Concomitant use of this medication with sympathomimetic agents (such as decongestants, appetite suppressants and amphetamine-like psychostimulants) which interfere with the catabolism of sympathomimetic amines, may occasionally cause a rise in blood pressure. Pseudoephedrine-containing products may antagonise the effect of certain classes of antihypertensives (e.g. beta blockers, methyl-dopa, reserpine, debrisoquine guanethidine) and increase the possibility of arrhythmias in digitalised patients.

Pholcodine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and tranquillizers (phenothiazines and tricyclic antidepressants).

Pholcodine may predispose patients to developing anaphylaxis with neuromuscular blocking agents.

4.6 Fertility, pregnancy and lactation


This product should not be used in pregnancy without medical advice.

Human and animal studies with paracetamol have not identified any risk to pregnancy or embryo-foetal development. Safe use of pseudoephedrine and pholcodine in pregnancy has not been established despite widespread use over many years. Caution should therefore be exercised by balancing the potential benefit of treatment to the mother against any possible hazards to the developing foetus.


This product should not be used whilst breastfeeding without medical advice.

Although paracetamol is excreted in breast milk, human studies with paracetamol have not identified any risk to lactation or the breast-fed offspring.

Pseudoephedrine is excreted in breast m milk in small amounts but the effect of this on breast fed infants is unknown.

It is not known whether pholcodine is excreted into breast milk.

Go to top of the page
4.7 Effects on ability to drive and use machines

Patients should be advised not to drive or operate machinery if affected by dizziness.

Go to top of the page
4.8 Undesirable effects

Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by System Organ Class and frequency.

The following convention has been utilised for the classification of undesirable effects: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000)

Adverse event frequencies have been estimated from spontaneous reports received through post-marketing data.


Body System

Undesirable Effect


Blood and Lymphatic System Disorders


Very rare

Immune System Disorders


Cutaneous hypersensitivity reactions including skin rashes, angiodema, and Steven Johnson syndrome. Very rare cases of serious skin reactions have been reported

Very rare

Respiratory, Thoracic and Mediastinal Disorders

Bronchospasm in patients sensitive to aspirin and other NSAIDs

Very rare

Hepatobiliary Disorders

Hepatic dysfunction

Very rare


Body System

Undesirable Effect


Psychiatric Disorders

Nervousness, insomnia


Agitation, restlessness


Hallucinations (particularly in children)


Nervous System Disorders



Cardiac Disorders

Tachycardia, palpitations


Vascular Disorders

Increased blood pressure*


Gastrointestinal disorders

Vomiting, dry mouth, nausea


Skin and Subcutaneous Tissue Disorders

Rash, allergic dermatitis**


Renal and Urinary Disorders

Dysuria, urinary retention***


*Increases in systolic blood pressure have been observed. At therapeutic doses, the effects of pseudoephedrine on blood pressure are not clinically significant.

**A variety of allergic skin reactions, with or without systemic features such as bronchospasm and angioedema have been reported following use of pseudoephedrine.

***Urinary retention is most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy.


Body System

Undesirable Effect


Immune System Disorders

Hypersensitivity reactions including skin rashes, angiodema, anaphylaxis


Gastrointestinal disorders

Nausea, vomiting


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Go to top of the page
4.9 Overdose

Symptoms and Signs


Paracetamol overdose may cause liver failure, which can lead to liver transplant and death.

There is a risk of poisoning with paracetamol particularly in elderly subjects, young children, patients with liver disease, cases of chronic alcoholism and in patients with chronic malnutrition. Overdosing may be fatal in these cases.

Symptoms generally appear within the first 24 hours and may comprise: nausea, vomiting, anorexia, pallor, and abdominal pain, or patients may be asymptomatic.

Overdose of paracetamol in a single administration in adults or in children can cause liver cell necrosis likely to induce complete and irreversible necrosis, resulting in hepatocellular insufficiency, metabolic acidosis and encephalopathy which may cause coma and death.

Simultaneously, increased levels of hepatic transaminases (AST, ALT), lactate dehydrogenase and bilirubin are observed together with increased prothrombin levels that may appear 12 to 48 hours after administration. Liver damage is likely in adults who have taken more than the recommended amounts of paracetamol. It is considered that excess quantities of toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested), become irreversibly bound to liver tissue.

Some patients may be at increased risk of liver damage from paracetamol toxicity. Risk Factors include: If the patient;

• Is on long-term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.

• Regularly consumes ethanol in excess of recommended amounts.

• Is likely to be glutathione depleted e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Emergency Procedure:

Immediate transfer to hospital.

Blood sampling to determine initial paracetamol plasma concentration. In the case of a single acute overdose, paracetamol plasma concentration should be measured 4 hours post ingestion.

Administration of activated charcoal should be considered if >150mg/kg paracetamol has been taken within 1 hour.

The antidote N-acetylcysteine, should be administered as soon as possible in accordance with National treatment guidelines

Symptomatic treatment should be implemented.


Pseudoephedrine overdose may result in symptoms due to central nervous system and cardiovascular stimulation e.g. excitement, restlessness, hallucinations, hypertension and arrhythmias. In severe cases, psychosis, convulsions, coma and hypertensive crisis may occur. Serum potassium levels may be low due to extracellular to intracellular shifts in potassium.


Treatment should consist of standard supportive measures. Beta blockers should reverse the cardiovascular complications and the hypokalemia.


Symptoms of pholcodine overdose may include nausea, drowsiness, restlessness, excitement and ataxia. Central nervous system depression, including respiratory depression, may develop but is unlikely to be severe unless other sedative agents have been co-ingested, including alcohol, or the overdose is very large.


Supportive and symptomatic care should be provided as required. If overdose is severe, naloxone may be helpful, particularly for patients with respiratory depression.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Paracetamol has analgesic and antipyretic actions.

Pseudoephedrine is a sympathomimetic agent with both direct and indirect effects on adrenergic receptors. Pholcodine is a cough suppressant with little analgesic activity.

Go to top of the page
5.2 Pharmacokinetic properties

Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 30 minutes to 2 hours after oral administration. Paracetarnol is distributed into most body tissues. It crosses the placenta and is present in breast milk.

Plasma protein binding is negligible at usual therapeutic concentrations. Paracetamol is metabolised predominantly in the liver and excreted in the urine mainly as the glucuronide and sulphate conjugates, with about 10% as glutathione conjugates. Less than 5% is excreted as unchanged paracetarnol. The elimination half life varies from about 1 to 4 hours.

Pseudoephedrine is rapidly and completely absorbed from the gastrointestinal tract after oral administration, with no presystemic metabolism. Peak plasma levels are achieved after 1-2 hours. The plasma half-life varies from 4.3-7.0 hours in adults. No protein binding data are available.

There is little metabolism of pseudoephedrine in man with approximately 90% being excreted in the urine unchanged. Approximately 1% is eliminated by hepatic metabolism, by N- demethylation to norpseudoephedrine.

As a weak base, the extent of renal excretion is dependent on urinary pH. At low urinary pH, tubular reabsorption is minimal and urine flow rate will not influence clearance of the drug. At high pH (>7.0), pseudoephedrine is extensively reabsorbed in the renal tubule and renal clearance will depend on urine flow rate.

Pholcodine is rapidly absorbed after oral administration and maximum plasma concentrations are attained at about 4-8 hours. The elimination half life ranges from 32 to 50 hours. The drug has a large volume of distribution and is only 23.5% protein bound. Pholcodine is metabolised in the liver but undergoes little conjugation with glucuronide and sulphate.

Approximately 25-50% of the drug is recovered unchanged in the urine.

Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Capsules contents

Sodium laurilsulfate

Sodium starch glycollate

Magnesium stearate

Hard gelatin capsule

(containing: Gelatin, Quinoline yellow (E104), Allura red (E129), Titanium dioxide (El71).)

Black print ink

(containing: Shellac, isopropyl alcohol, black iron oxide (E172), N-butyl alcohol, propylene glycol, ammonium hydroxide.)

Go to top of the page
6.2 Incompatibilities

Not applicable.

Go to top of the page
6.3 Shelf life

3 years.

Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Store in the original package.

Go to top of the page
6.5 Nature and contents of container

PVC/PVdC blister tray with aluminium foil lid. Pack sizes: 8, 10, 12, 16, 20 or 24 tablets. Not all pack sizes may be marketed.

Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.

Go to top of the page

GlaxoSmithKline Consumer Healthcare (Ireland) Ltd

12 Riverwalk

CityWest Business Campus

Dublin 24


Go to top of the page

PA 678/100/1

Go to top of the page

Date of first authorisation: 04 November 2003

Date of last authorisation: 04 November 2008

Go to top of the page

July 2017

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

   Pseudoephedrine Hydrochloride